136 results
8-K
EX-99
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
11 Aug 04
Other events
12:00am
858/550-7830
LIGAND ANNOUNCES RECENTLY FILED CLASS ACTION LAWSUIT
SAN DIEGO, CA, August 11, 2004 - Ligand … Vice President and Chief
Financial Officer, have been named as defendants in a purported shareholder
class action lawsuit alleging violations
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 May 19
Entry into a Material Definitive Agreement
4:28pm
relating to Evomela, and on May 23, 2019, the Company filed a complaint as further described below (the “Alembic Lawsuit”). Acrotech agreed to pay … a specified percentage of fees and costs incurred by the Company with respect to the Alembic Lawsuit, and the Company and Acrotech also agreed to certain
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
11 Aug 04
Other events
12:00am
and anticipates that additional actions may be filed
in the future. Ligand believes that the allegations in the lawsuit are without
merit. Ligand … will successfully
defend any lawsuit, including any purported securities class action. Additional
information concerning these and other risk factors
10-Q
r4bvx
9 May 96
Quarterly report
12:00am
8-K
EX-10.2
gofhcqj06
4 Aug 06
Ligand Announces that David Robinson Steps Down as Chairman, President and CEO; Henry Blissenbach Named Chairman and Interim CEO
12:00am